Merck & Co to plough on in Alzheimer's after latest failure

14 February 2018

US pharma giant Merck & Co (NYSE: MRK) has halted a Phase III trial of verubecestat (MK-8931) in people with prodromal Alzheimer’s disease (AD) based on a recommendation by the external Data Monitoring Committee (eDMC).

Verubecestat is a small molecule inhibitor of the beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) and it had been seen as a promising prospect even in the graveyard of hopeful candidates that is the Alzheimer’s drug development space.

But a trial of verubecestat in patients with more advanced disease was stopped last year and now the APECS study has gone the same way. The eDMC concluded that it was unlikely that a positive benefit to risk ratio could be established if the trial continued.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK